Quaker Chemical (KWR) investor relations material

Executive summary

• Q3 2025 net sales reached $494 million, up 7% year-over-year, driven by 3% organic volume growth, 5% from acquisitions, and favorable currency, with strong performance in Asia-Pacific and new business wins.

• Adjusted EBITDA was $83 million, up 5% year-over-year, with a margin of 16.8%; adjusted EPS rose 10% to $2.08.

• Net income for Q3 2025 was $30.5 million ($1.75 per diluted share), down from $32.3 million in Q3 2024, reflecting higher costs and restructuring.

• Integration of Dipsol and other acquisitions contributed to sales and margin improvements.

• Maintained operational discipline, cost controls, and strategic execution, supporting profitability and sustainable growth.

Financial highlights

• Q3 2025 net sales were $494 million (+7% YoY); adjusted EBITDA was $83 million (+5% YoY); adjusted EBITDA margin was 16.8%.

• Non-GAAP EPS was $2.08 (up from $1.89 YoY); GAAP EPS was $1.75.

• Gross margin was 36.8% (down from 37.3% YoY); operating cash flow for Q3 was $51 million.

• Net debt as of September 30, 2025, was $703 million; cash and equivalents at $172 million.

• SG&A expenses and restructuring charges increased due to acquisitions and cost-saving initiatives.

Outlook and guidance

• Management expects continued revenue and adjusted EBITDA growth in Q4 2025, with solid cash flow generation and normal seasonality.

• Macroeconomic softness and volatility in effective tax rates are expected to persist through 2025, with stabilization possible in 2026.

• Additional restructuring actions are planned through 2026, targeting $40 million in annualized cost savings.